Next Science Ltd (NXS)
20mins delayed
Movement
1 Year Return
Next Science Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $128.85 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
NXS Statistics
07 April
606 / 2,256
ASX Size Rank
1yr Return
vs Sector (1yr)
-49.38%
vs ASX 200 (1yr)
+4.47%
$128.85 million
Market Cap
Share Issue
107.38 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
07 April
N/A
PE Ratio
EPS ($)
-0.124
Earnings Yield
-10.29%
NTA ($)
0.14
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Next Science Limited (NXS) is a medical technology with a research and development centre in Florida, USA. NXS has four FDA cleared products currently available in the US market to treat and manage surgical site infections and chronic wounds.
Upcoming Calendar
| 21 Aug 2020 | Report (Interim) |
| 26 Feb 2021 | Report (Prelim) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
NXS is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Mark Raymond Compton | Non-Executive Director | Oct 2018 |
|
| Mr George Savvides | Non-Executive Chairman, Non-Executive Director | Jul 2018 |
|
| Mr Bruce Alan Hancox | Non-Executive Director | Oct 2017 |
|
| Mr Dan Spira | Non-Executive Director | Oct 2017 |
|
| Mrs Aileen Stockburger | Non-Executive Director | Oct 2018 |
|
| Ms Judith Mitchell | Managing Director | Oct 2017 |
|
| Jacqueline Butler | Chief Financial Officer | N/A | |
| Jon Swanson | Chief Operating Officer | N/A | |
| Matthew Myntti | Chief Technology Officer | N/A | |
| Gillian Nairn | Company Secretary | N/A |
Director Transactions
NXS directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 19/12/19 | Dan Spira | Issued | 8,865 | $2.820 | $24,999 | Director remuneration. |
| 19/12/19 | Aileen Stockburger | Issued | 7,977 | $2.820 | $22,495 | Director remuneration. |
| 25/09/19 | Dan Spira | Issued | 27,864 | $1.674 | $46,643 | Director remuneration. |
| 25/09/19 | Aileen Stockburger | Issued | 25,577 | $1.661 | $42,475 | Director remuneration. |
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
No data available. Most companies release Top 20 Shareholders data in their Annual Report but it's not compulsory.
NXS Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
NXS Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2019 | $4.11 | 28 June |
| 2014 | $0.013 | 30 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Research, development and commercialisation of technologies which solve issues in human health caused by biofilms.
Incorporated: --
Suite 1902, Level 19, Tower A The Zenith Building, 821 Pacific Hwy
Chatswood NSW 2067
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.